Nu-Med Plus Reports Continued Net Loss and No Revenue in Q2 2025

Nu-Med Plus, Inc. reported its financial results for the second quarter of 2025, revealing a continued lack of revenue and a net loss of $11,665 for the three months ending June 30, 2025, compared to a net loss of $17,287 for the same period in 2024. For the first half of 2025, the company also reported no revenue, with a net loss of $31,598, an improvement from the $39,112 loss recorded in the first half of 2024. Operating expenses decreased to $10,419 in the second quarter of 2025 from $16,040 in the prior year, primarily due to reduced dues and subscriptions.

As of June 30, 2025, Nu-Med Plus had total assets of $8,163, down from $9,373 at the end of 2024. Current liabilities increased to $254,857 from $224,469, contributing to a working capital deficiency of $246,694. The company’s accumulated deficit grew to $9,924,930, up from $9,893,332 at the end of 2024. The financial statements indicate that the company has been relying on loans from shareholders and the sale of stock to cover its expenses, as it has not generated any revenue to date.

Strategically, Nu-Med Plus has focused on developing technologies utilizing nitric oxide for medical applications, including a hospital delivery system and a portable device for inhalation therapy. However, product development has been suspended pending a capital infusion, which the company estimates will require approximately $1.2 million over the next twelve months. The company has not yet submitted any products for FDA approval, which is necessary for commercial sales in the medical field.

The company’s operational metrics reflect a challenging environment, with no customer counts or product adoption rates reported. The management has acknowledged that without additional funding, the company may not be able to continue operations or execute its business plan. As of June 30, 2025, Nu-Med Plus had cash reserves of only $863, significantly down from $2,373 at the end of the previous fiscal year. The company is currently funded through September 30, 2025, but anticipates needing $300,000 for corporate overhead and an additional $900,000 for ongoing product development.

Looking ahead, Nu-Med Plus has expressed uncertainty regarding its ability to secure the necessary funding to advance its product development and operational plans. The company is actively seeking additional financing through private stock sales and loans from investors. However, the lack of revenue and reliance on external funding sources raise substantial doubt about its ability to continue as a going concern. The management has indicated that the results of operations for the first half of 2025 are not necessarily indicative of future performance, emphasizing the need for strategic financial planning and capital acquisition.